estim
million
peopl
infect
dengu
viru
denv
yearli
mostli
southern
asia
northern
latin
america
infect
denv
caus
spectrum
outcom
group
four
categori
increas
clinic
sever
infect
symptom
undifferenti
fever
classic
dengu
fever
df
dengu
haemorrhag
fever
dhf
afflict
latter
two
categori
exhibit
overt
symptom
usual
seek
medic
attent
estim
df
dhf
togeth
result
hospit
death
per
year
http
howev
total
number
peopl
debilit
ill
caus
denv
like
ten
million
annual
current
vaccin
effect
therapeut
prevent
treat
dfdhf
commerci
avail
sever
promis
denv
vaccin
approach
report
current
evalu
human
clinic
trial
http
wwwclinicaltrialsgov
sever
small
molecul
monoclon
antibodi
produc
promis
result
drug
develop
studi
addit
nucleicacidbas
strategi
employ
propynesubstitut
phosphorothio
small
interf
shown
suppress
denv
replic
mammalian
cell
cultur
howev
time
write
clinic
trial
regist
unit
state
food
drug
administr
therapeut
agent
treat
denv
infect
progress
http
wwwclinicaltrialsgov
dengu
virus
occur
complex
four
distinct
serotyp
compos
mani
genotyp
strain
variou
strain
serotyp
caus
sever
diseas
four
serotyp
denv
form
singl
speci
genu
flaviviru
famili
denv
genom
kb
singlestrand
rna
molecul
posit
polar
contain
singl
open
read
frame
orf
flank
untransl
region
utr
orf
translat
singl
polyprotein
co
posttransl
cleav
produc
matur
viral
protein
utr
contain
conserv
sequenc
structur
import
role
regul
mani
aspect
viral
life
cycl
includ
translat
rna
synthesi
virion
dengu
virus
gener
pathogen
mice
howev
number
murin
model
studi
denv
exist
although
none
thought
accur
mirror
denv
pathogenesi
mice
lack
gamma
interferon
receptor
gene
therefor
crippl
innat
immun
system
adapt
immun
system
consid
function
howev
use
success
model
system
denv
vaccin
certain
strain
caus
viraemia
detect
high
titr
number
tissu
intraperiton
ip
administr
mice
infect
neuroadapt
strain
new
guinea
c
ngc
mochizuki
strain
typic
suffer
mortal
day
recent
schul
et
show
ip
administr
unadapt
produc
transient
viraemia
mice
antivir
drug
candid
could
evalu
effect
viraemia
cytokin
level
blood
test
phosphorodiamid
morpholino
oligom
pmo
nonion
oligonucleotid
analogu
contain
four
base
dna
possess
backbon
compos
morpholin
ring
phosphorodiamid
intersubunit
linkag
instead
deoxyribos
phosphodiest
compon
antisens
pmo
report
effect
ebola
felin
vivo
pmo
deliveri
cell
much
improv
coval
conjug
argininerich
cellpenetr
peptid
cpp
cppconjug
pmo
ppmo
shown
gener
potent
inhibit
denv
cell
cultur
west
nile
viru
wnv
polioviru
pv
murin
influenza
infect
cell
cultur
mous
model
experi
variou
cpp
conjug
pmo
indic
residu
peptid
name
contain
four
repeat
acid
arginin
appear
characterist
allow
consider
potenti
therapeut
previou
report
show
ppmo
design
either
termin
nucleotid
nt
cyclizationsequ
region
denv
genom
highli
effect
inhibit
denv
amplif
cell
report
document
ppmo
design
correspond
region
wnv
flavivirus
effect
cell
cultur
intent
studi
report
extend
previou
observ
explor
efficaci
ppmo
denv
vivo
found
ppmo
target
denv
sequenc
region
effect
vivo
extend
averag
surviv
mice
day
compar
ppmo
variou
length
cell
cultur
design
either
antidenv
efficaci
found
ppmo
base
effect
shorter
longer
ppmo
target
region
pharmacokinet
analysi
indic
ppmo
distribut
readili
liver
persist
least
day
sever
toxicolog
analys
indic
repeat
ip
dose
ppmo
mgkg
deleteri
effect
health
noninfect
mice
cell
cultur
experi
strain
deriv
previous
describ
infecti
cdna
clone
wildtyp
use
vivo
studi
stock
mouseneuroadapt
strain
new
guinea
c
ngc
cdc
fort
collin
co
use
viral
infecti
titr
determin
plaqu
assay
vero
cell
previous
determin
pfu
ngc
found
lethal
mice
cell
cultur
experi
vero
cell
grown
modifi
medium
imdm
hyclon
logan
ut
usa
supplement
heatinactiv
fb
hyclon
sodium
bicarbon
gl
penicillin
g
uml
streptomycin
sulphat
mgl
indic
fb
medium
plate
pmo
synthes
avi
biopharma
inc
corval
usa
method
describ
cpp
rxr
design
r
arginin
x
acid
b
betaalanin
coval
conjug
end
pmo
often
abbrevi
ppmo
report
compound
synthes
purifi
analys
avi
biopharma
inc
method
describ
sixteen
ppmo
prepar
figur
three
ppmo
also
prepar
pmo
prepar
fluorescein
fl
conjug
end
use
cell
uptak
evalu
eight
antisens
ppmo
compound
design
duplex
complementari
basepair
region
nt
seven
compound
design
duplex
cycliz
sequenc
cs
nt
genbank
access
genom
rna
denv
region
previous
shown
product
target
site
pmo
random
sequenc
gc
content
dscr
prepar
pmo
ppmo
use
neg
control
nonsequencespecif
effect
respect
chemistri
prior
use
lyophil
pmo
ppmo
resuspend
concentr
mm
pb
store
dark
vivo
studi
pmo
ppmo
constitut
endotoxinfre
pb
cell
cultur
incub
took
place
vero
cell
seed
plate
cell
per
well
grown
confluenc
cell
wash
twice
pb
incub
ml
imdm
lack
fb
fb
alon
medium
contain
appropri
concentr
ppmo
compound
h
medium
remov
cell
infect
moi
pfucel
ml
fb
h
infect
period
inoculum
remov
cell
wash
twice
pb
fresh
fb
without
ppmo
concentr
infect
ad
day
infect
aliquot
medium
remov
well
store
previous
plaqu
titrat
plaqu
titrat
perform
agaros
overlay
vero
cell
monolay
grown
plate
describ
investig
rel
uptak
ppmo
variou
length
vero
cell
cultur
fb
plate
confluenc
cell
wash
treat
fb
contain
fluoresceinlabel
ppmo
h
treatment
cell
wash
pb
treat
trypsin
min
trypsin
inactiv
addit
medium
contain
fb
cell
pellet
g
wash
twice
cold
pb
resuspend
pb
contain
fb
suspens
analys
beckman
coulter
cytomet
data
process
use
fc
express
denovo
softwar
thornhil
ontario
canada
prior
initi
either
two
vivo
viral
inhibit
experi
studi
effect
prospect
dose
regimen
assess
toxic
noninfect
mice
first
antivir
studi
group
four
mice
receiv
two
ip
dose
separ
h
pb
pb
contain
either
mgkg
pmo
dscr
mgkg
ppmo
dscr
preliminari
second
antivir
studi
group
six
mice
receiv
ip
dose
pb
pb
contain
mgkg
ppmo
day
day
mice
observ
daili
abnorm
appear
behaviour
includ
lethargi
hunch
ruffl
fur
diarrhoea
weigh
per
week
also
day
second
experi
week
durat
experi
first
vivo
antivir
studi
group
four
mice
receiv
ip
administr
pb
pmo
ppmo
h
h
ip
inocul
pfu
ngc
mice
observ
daili
sign
sever
diseas
survivor
weigh
day
postinfect
dpi
second
experi
group
six
mice
except
pb
control
group
five
mice
receiv
total
nine
ip
treatment
pb
ppmo
h
h
viru
challeng
day
day
postchalleng
pfu
ngc
one
mous
group
receiv
seven
postchalleng
ppmo
treatment
two
ppmo
treatment
h
viru
challeng
inject
use
pb
vehicl
antivir
experi
includ
noninfect
nontreat
mice
control
whole
blood
sampl
collect
clean
ml
tube
contain
edta
immedi
centrifug
rpm
min
plasma
portion
collect
fresh
amber
tube
organ
homogen
immedi
collect
buffer
gbioscienc
st
loui
mo
usa
centrifug
supernat
collect
fresh
amber
tube
plasma
tissu
homogen
immedi
analys
fluorometr
excit
emiss
wavelength
nm
respect
use
micropl
fluoresc
reader
biotek
instrument
inc
winooski
vt
usa
pharmacokinet
pk
profil
character
compartment
analysi
blood
sampl
collect
h
time
point
follow
singledos
ip
inject
plasma
concentr
versu
time
profil
fit
twocompartment
open
model
use
pk
solut
softwar
summit
research
servic
montros
co
usa
fit
pk
paramet
includ
appar
elimin
halflif
plasma
clearanc
clpl
volum
distribut
vd
area
curv
versu
time
curv
auc
auc
estim
use
loglinear
trapezoid
method
plasma
data
fit
equat
c
c
plasma
concentr
time
b
intercept
term
distribut
rate
constant
elimin
rate
constant
error
bar
report
repres
mean
standard
deviat
statist
analysi
consist
linear
regress
analysi
calcul
graphpad
prism
softwar
graphpad
softwar
san
diego
ca
usa
p
valu
consid
statist
signific
previous
shown
two
treatment
cell
cultur
ppmo
one
treatment
start
h
anoth
start
h
inocul
period
could
produc
titr
reduct
sever
order
magnitud
compar
control
sever
day
sought
investig
antivir
effect
similar
dose
regimen
vivo
set
first
evalu
effect
prospect
dose
regimen
health
noninfect
anim
intraperiton
administr
pmo
mice
report
produc
detect
toxic
even
high
gener
accept
toxic
caus
ppmo
due
peptid
compon
therefor
consid
evalu
singl
ppmo
compound
repres
offtarget
effect
like
result
ppmo
employ
regimen
group
mice
treat
twice
h
apart
pb
dscr
pmo
dscr
ppmo
found
suffer
weight
loss
appar
illeffect
ensu
day
monitor
data
shown
establish
subtox
dose
regimen
noninfect
anim
regimen
pmo
ppmo
employ
vivo
viral
inhibit
challeng
figur
show
surviv
mice
treat
infect
ngc
six
pmo
ppmo
evalu
two
gener
statist
signific
extens
surviv
compar
pbstreat
group
member
ppmotreat
group
surviv
averag
day
longer
p
respect
figur
b
three
four
mice
treat
ppmo
still
aliv
day
wherea
three
four
mice
pb
dscr
ppmotreat
group
die
day
furthermor
ppmo
group
show
littl
group
moder
weightloss
day
figur
reflect
enhanc
surviv
observ
effort
improv
potenc
ppmo
target
denv
region
panel
ppmo
vari
length
direct
two
region
synthes
use
cell
cultur
trial
eight
ppmo
base
long
ppmo
base
design
respect
figur
cell
incub
ppmo
h
prior
infect
viral
titr
assess
dpi
figur
show
ppmo
base
sequenc
effect
reduc
viral
titr
respect
compar
mock
dscrtreat
control
dpi
effect
result
reduct
titr
dpi
note
viral
titr
reduct
produc
effect
compound
consider
greater
day
day
indic
viru
rebound
effect
drug
manner
consist
report
similar
previou
experi
evalu
effect
ppmo
time
cell
result
figur
show
ppmo
base
length
consider
higher
antivir
activ
shorter
longer
ppmo
target
region
determin
whether
pmotransport
capac
compon
ppmo
affect
pmo
length
evalu
uptak
ppmofl
differ
length
noninfect
vero
cell
cell
incub
ppmofl
base
length
figur
h
experiment
condit
similar
use
antivir
experi
figur
presenc
fluorescein
evalu
flow
cytometri
observ
three
ppmo
enter
cell
ppmofl
produc
nearli
ident
signal
intens
differ
cell
entri
characterist
three
ppmofl
observ
data
shown
second
vivo
experi
ppmo
use
number
dose
increas
nine
first
antivir
vivo
experi
preliminari
toxic
evalu
prospect
dose
regimen
carri
noninfect
mice
group
six
mice
treat
ip
day
day
consecut
pb
ppmo
weight
appear
monitor
week
weight
loss
occur
either
group
durat
monitor
period
figur
second
viral
inhibit
challeng
group
mice
except
one
receiv
two
pb
ppmotreat
seven
treatment
infect
ngc
one
group
receiv
preinfect
treatment
seven
postinfect
treatment
ppmo
mice
receiv
pre
postinfect
treatment
live
averag
day
longer
combin
treatment
live
day
longer
pbstreat
control
p
respect
treatment
group
group
receiv
postinfect
treatment
outliv
pb
control
day
respect
result
statist
signific
figur
averag
surviv
pbstreat
mice
sever
day
longer
experi
figur
first
vivo
experi
figur
probabl
lower
challeng
dose
ngc
viru
use
previou
unrel
experi
mice
surviv
averag
day
follow
ip
challeng
ngc
dose
pfu
respect
richard
kinney
unpublish
result
mice
pb
dscr
ppmotreat
group
die
day
wherea
half
mice
combin
group
live
day
bodi
weight
measur
reflect
rel
stabl
health
surviv
anim
day
figur
linear
log
plot
plasma
concentr
versu
time
curv
singl
mgkg
inject
ppmofl
balbc
mice
shown
figur
b
summari
key
pk
estim
present
tabl
data
point
repres
mean
sd
triplic
valu
peak
plasma
concentr
cmax
observ
mgl
tmax
h
follow
administr
ppmofl
distribut
halflif
h
elimin
halflif
observ
h
auc
estim
correspond
volum
distribut
vd
lkg
bodi
weight
plasma
clearanc
lh
figur
repres
tissu
ppmofl
level
brain
liver
spleen
balbc
mice
differ
time
point
follow
singledos
administr
figur
b
show
tissu
distribut
follow
singl
daili
inject
consecut
day
day
washout
time
point
follow
day
treatment
three
organ
evalu
liver
observ
site
highest
accumul
brain
accumul
least
amount
ppmofl
entir
period
figur
correspond
tissu
concentr
shown
tabl
linear
regress
analysi
show
liver
accumul
ppmofl
fastest
posit
slope
compar
brain
slope
spleen
slope
presenc
ppmofl
tissu
detect
level
earli
h
indic
rapid
tissu
distribut
vascular
space
peripher
tissu
also
tissu
plasma
concentr
ratio
tmax
brain
liver
spleen
respect
ppmofl
level
chang
significantli
day
washout
period
last
dose
figur
balbc
mice
receiv
ip
dose
per
day
day
mgkg
ppmofl
weigh
observ
daili
sign
clinic
ill
cours
day
studi
serum
chemistri
haematolog
bodi
weight
also
monitor
part
safeti
evalu
chang
anim
behaviour
appear
treatment
observ
shown
figur
indic
show
signific
chang
treatment
increas
serum
cholesterol
p
decreas
haematocrit
p
haemoglobin
p
pack
cell
volum
p
red
blood
cell
rbc
count
p
treatment
indic
revert
level
compar
untreat
control
day
washout
period
shown
figur
bodi
weight
anim
increas
g
durat
studi
littl
variat
individu
data
shown
first
two
vivo
experi
carri
studi
pmo
compar
ppmo
antivir
efficaci
denvinfect
mice
pmo
produc
signific
treatment
benefit
wherea
ppmo
treat
mice
show
statist
signific
increas
surviv
time
figur
ppmo
variou
length
compar
cell
cultur
antidenv
efficaci
ppmo
base
found
effect
abl
reduc
viral
titr
sever
order
magnitud
present
cell
cultur
medium
antivir
effect
also
greater
report
previous
ppmo
made
differ
cpp
earlier
report
concentr
exhibit
antivir
activ
viru
vero
cell
ppmo
produc
high
efficaci
length
versu
activ
evalu
use
second
mous
studi
higher
number
dose
longer
time
period
dose
occur
employ
first
vivo
experi
surviv
benefit
antisens
ppmotreat
group
extend
averag
week
second
vivo
experi
hypothes
employ
greater
number
dose
ppmo
effect
length
first
week
postinfect
concomit
lower
still
sever
ngc
challeng
dose
would
limit
viral
replic
suffici
permit
develop
fulli
protect
immun
respons
pbstreat
group
live
averag
day
second
experi
compar
day
first
experi
experi
effect
ppmo
produc
day
extens
surviv
time
protect
denvinduc
weight
loss
period
week
compar
control
figur
difficult
compar
vivo
result
studi
obtain
potenti
antidenv
drug
report
literatur
time
write
studi
surviv
time
employ
endpoint
evalu
potenti
drug
use
mice
result
strongli
suggest
ppmo
treatment
suppress
viral
titr
vivo
period
sever
day
residu
viru
abl
rebound
number
day
treatment
cessat
similar
pattern
also
observ
cell
cultur
studi
report
altern
likewis
untest
hypothesi
viru
resist
effect
ppmo
aros
time
respons
treatment
date
howev
report
literatur
viral
mutat
aris
respons
ppmo
treatment
anim
investig
sequenc
viru
mice
treat
ppmo
highli
activ
vivo
found
mutat
ppmotarget
region
current
vivo
experi
includ
enough
anim
evalu
amount
sequenc
viru
blood
tissu
biolog
denv
infect
mous
consid
quit
differ
natur
denv
infect
human
nevertheless
benefit
afford
mice
ppmo
studi
promis
result
level
viraemia
affect
durat
sever
dengu
diseas
drug
capabl
limit
viral
replic
could
reason
expect
benefici
patient
second
vivo
experi
show
postinfect
treatment
alon
effect
pre
postinfect
treatment
ppmo
figur
although
result
indic
earli
intervent
ppmo
necessari
maximum
protect
effect
possibl
experi
conclud
whether
type
technolog
ultim
clinic
use
pathogenesi
dfdhf
human
character
wide
varieti
clinic
progress
includ
subset
patient
remain
viraem
harbour
viru
tissu
period
time
beyond
onset
consid
larg
number
total
case
dfdhf
like
agent
effect
reduc
viru
replic
nontox
manner
would
find
util
report
literatur
indic
highli
effect
ppmo
studi
vari
length
determin
rel
antivir
efficaci
ppmo
variou
length
analys
two
panel
seven
eight
ppmo
effect
ppmo
panel
base
length
although
bind
affin
oligonucleotid
singl
strand
nucleic
acid
reflect
melt
point
temperatur
increas
function
oligonucleotid
length
number
design
factor
affect
function
perform
antisens
previous
shown
ppmo
target
denv
terminu
interfer
correspond
ppmo
interfer
wnv
rna
cap
ppmo
shown
interfer
rna
synthesi
thu
ppmo
target
region
like
work
interf
differ
aspect
viral
life
cycl
despit
differ
mechan
action
effect
ppmo
panel
similar
length
limit
number
mice
avail
us
use
balbc
mice
pktoxic
analysi
compound
previous
shown
stabl
human
serum
least
pk
profil
base
plasma
concentr
data
monitor
h
follow
singl
ip
inject
peak
plasma
concentr
observ
tmax
h
follow
inject
indic
rapid
transfer
site
inject
vascular
space
observ
distribut
halflif
h
high
volum
distribut
vd
auc
detect
level
ppmofl
observ
brain
liver
spleen
h
min
postdos
indic
ppmofl
distribut
fairli
rapidli
tissu
tissu
plasma
concentr
ratio
liver
spleen
tmax
provid
indic
ppmofl
rapidli
penetr
tissu
three
tissu
test
liver
observ
primari
site
accumul
brain
accumul
minim
amount
compound
assum
higher
perfus
liver
mlmin
rat
compar
spleen
mlmin
brain
mlmin
contribut
observ
pattern
attribut
low
cerebr
uptak
presenc
blood
brain
barrier
shown
figur
b
level
ppmofl
brain
liver
spleen
chang
significantli
day
follow
cessat
day
treatment
period
observ
indic
tissu
retain
compound
provid
use
inform
prospect
dose
frequenc
futur
studi
although
liver
consid
major
target
organ
denv
replic
involv
liver
pathogenesi
denv
infect
denv
antigen
rna
detect
variou
cell
liver
safeti
assess
ppmo
base
chang
behaviour
appear
bodi
weight
serum
chemistri
panel
haematolog
balbc
mice
nine
daili
treatment
signific
chang
serum
chemistri
haematolog
treatment
elev
serum
cholesterol
decreas
haematocrit
haemoglobin
pack
cell
volum
red
blood
cell
rbc
count
howev
chang
appear
impact
overal
health
anim
indic
revert
level
compar
untreat
control
day
washout
period
shown
figur
fact
total
bilirubin
alter
treatment
period
suggest
observ
decreas
red
blood
cell
count
haematocrit
pack
cell
volum
result
interfer
red
blood
cell
product
rather
haemolysi
cell
data
demonstr
denv
ppmo
possess
favour
safeti
profil
kinet
behaviour
data
studi
like
prove
use
design
futur
vivo
studi
ppmo
result
two
vivo
antivir
experi
pk
analysi
show
resid
time
ppmo
sever
day
suggest
extend
treatment
period
perhap
less
frequent
dose
could
produc
longer
extens
surviv
time
observ
studi
studi
conduct
contract
research
develop
agreement
avi
biopharma
center
diseas
control
c
r
e
b
p
l
work
work
compani
manufactur
antisens
oligom
use
report
remain
author
none
declar
